Clinical Trial Detail

NCT ID NCT03836352
Title Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors ImmunoVaccine Technologies, Inc. (IMV Inc.)
Indications

lung non-small cell carcinoma

ovary epithelial cancer

Advanced Solid Tumor

peritoneum cancer

hepatocellular carcinoma

fallopian tube cancer

transitional cell carcinoma

Therapies

DPX-Survivac + Pembrolizumab

Cyclophosphamide + DPX-Survivac + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.